Nurix Therapeutics
Quarterly Financials
| Values in thousands | 2026-08-31 | 2026-05-31 | 2026-02-28 | 2025-11-30 |
|---|---|---|---|---|
Revenue | $673,064 | $9,043 | $6,252 | $13,577 |
Gross Profit | 670,925 | 5,193 | -77,885 | 8,946 |
EBITDA | 565,552 | -85,956 | -83,398 | -73,590 |
EBIT | 563,413 | -89,806 | -87,174 | -78,221 |
Net Income | 549,807 | -89,535 | -87,174 | -78,221 |
Net Change In Cash | 673,064 | 9,043 | 6,252 | 13,577 |
Free Cash Flow | 614,239 | -98,509 | -72,959 | -72,963 |
Cash | 720,242 | 67,685 | 71,195 | 246,960 |
Basic Shares | 116,152 | 111,084 | 110,071 | 95,089 |
Annual Financials
| Values in thousands | 2025-11-30 | 2024-11-30 | 2023-11-30 | 2022-11-30 |
|---|---|---|---|---|
Revenue | $83,980 | $54,549 | $76,987 | $38,627 |
Gross Profit | 65,123 | -167,083 | -112,161 | 38,627 |
EBITDA | -244,841 | -176,871 | -130,294 | -173,059 |
EBIT | -263,697 | -193,299 | -143,948 | -183,867 |
Net Income | -264,457 | -193,569 | -143,948 | -166,045 |
Net Change In Cash | 83,980 | 54,549 | 76,987 | 38,627 |
Cost of Revenue | -15,417 | |||
Free Cash Flow | -263,467 | -181,857 | -89,766 | -172,051 |
Cash | 246,960 | 109,997 | 54,627 | 64,474 |
Basic Shares | 86,666 | 67,120 | 54,337 | 48,607 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-08-31 | $4.73 |
2026-05-31 | -$0.81 |
2026-02-28 | -$0.79 |
2025-11-30 | -$0.82 |